I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...

I-Mab (IMAB) stock jumped 15% Monday after the biotech company said it plans to focus on developing givastomig for the treatment of gastric cancers. Read more here.

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving beyond cancer and rare disease.

Russia and other hostile states have become increasingly brazen in adopting “gray zone” attacks against Europe and the United States, leaving defense officials with a dilemma: How to respond ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

Al Jazeera’s Moath al-Kahlout, one of the few journalists in northern Gaza, has been to the scene of an Israeli attack. Hamas tells news agencies it has approved a list of 34 captives to be ...

Tarpon Springs, Florida, celebrated Epiphany on Monday, January 6, 2025, a deeply rooted observance in the city's Greek heritage and one of the most significant celebrations in the United States. This ...